GlassScriptPhysician profile
Linda S Gemer
NPI 1558318782
$2,449.28
in general payments reported to CMS, 2019-2025
34 companies · $622 in 2025
The $622 reported for 2025 was more than what 78% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $244 · 2020: $222 · 2021: $96.26 · 2022: $156 · 2023: $332 · 2024: $777 · 2025: $622.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,731.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,730.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $229.75 | 2019-2025 | Imfinzi, Enhertu |
| Abbvie INC. | $178.59 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $167.08 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Amgen INC. | $164.59 | 2019-2023 | Vectibix, Xgeva, Kyprolis |
| Novartis Pharmaceuticals Corporation | $155.77 | 2023-2025 | |
| Pfizer INC. | $140.49 | 2020-2025 | |
| Janssen Biotech, INC. | $123.20 | 2021-2025 | Erleada, Tecvayli, Darzalex |
| Lilly USA, LLC | $113.52 | 2020-2024 | Verzenio, Jaypirca, Retevmo |
| Coherus Oncology, INC. | $106.41 | 2022-2025 | Loqtorzi, Udenyca |
| E.R. Squibb & Sons, L.L.C. | $83.79 | 2019-2024 | Opdivo |
| Incyte Corporation | $76.21 | 2023-2025 | Jakafi |
| Sobi, INC | $69.66 | 2023-2024 | |
| Emd Serono, INC. | $65.68 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $64.65 | 2024-2025 | Libtayo |
| Astellas Pharma US INC | $62.99 | 2019-2023 | Xtandi |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $58.79 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $56.23 | 2020-2024 | Ninlaro |
| Blueprint Medicines Corporation | $53.90 | 2024-2025 | Ayvakit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.14 | 2023-2025 | Gilotrif |
| Eisai INC. | $48.75 | 2024-2025 | |
| Seagen INC. | $45.54 | 2020-2023 | Adcetris |
| Novo Nordisk INC | $45.45 | 2020-2023 | Rebinyn |
| Genentech USA, INC. | $45.38 | 2025 | Venclexta |
| Celgene Corporation | $37.51 | 2019-2020 | |
| Daiichi Sankyo INC. | $25.05 | 2025 | Vanflyta |
| Jazz Pharmaceuticals INC. | $23.87 | 2022 | |
| Karyopharm Therapeutics INC. | $22.81 | 2020 | |
| Mirati Therapeutics, INC. | $21.54 | 2023 | Krazati |
| Kyowa Kirin, INC. | $19.94 | 2024 | Poteligeo |
| Glaxosmithkline, LLC. | $19.39 | 2023 | Ojjaara |
| Siemens Medical Solutions USA, INC. | $18.75 | 2022 | |
| Canon Medical Systems USA, INC. | $18.11 | 2021 | |
| Alexion Pharmaceuticals, INC. | $17.69 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $17.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Linda Gemer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.